Compugen (CGEN)

History and Background

Compugen Ltd. was founded in 1993. Initially focused on computational genomics, it has evolved into a clinical-stage drug discovery and development company focusing on cancer immunotherapy.

Core Business Areas

• Immuno-oncology: Discovery and development of novel therapeutics targeting cancer immunotherapy. Their focus is on discovering first-in-class cancer immunotherapies by utilizing their computational discovery platform.

Leadership and Structure

The leadership team consists of a CEO, CFO, CSO and other VPs. The organizational structure follows a functional model common in biotech, with research, development, clinical, and commercial operations.

Key Offerings

• COM701: A first-in-class anti-PVRIG antibody designed to block the interaction of PVRIG with its ligands, PVRL1 (nectin-1) and PVRL2 (nectin-2). Currently in Phase 1/2 clinical trials in combination with immune checkpoint inhibitors. No market share or revenue yet as it is in clinical development. Competitors developing similar PVRIG inhibitors include iTeos Therapeutics (ITOS). Other competitors include the established checkpoint inhibitors such as Keytruda by Merck.
• BAY 1905254 (formerly COM902): A first-in-class anti-TIGIT antibody being developed by Bayer under a license agreement. It is in clinical development and targeting TIGIT for cancer immunotherapy. No market share or revenue yet as it is in clinical development. Competitors developing similar TIGIT inhibitors include Gilead Sciences (Arcus Bio).

Industry Overview

The immuno-oncology market is a rapidly growing segment of the pharmaceutical industry, focused on developing therapies that harness the body's immune system to fight cancer.

Positioning

Compugen is positioned as an innovator in the immuno-oncology space, leveraging its computational discovery platform to identify novel drug targets. Their competitive advantage lies in their target discovery capabilities and first-in-class drug candidates.

Total Addressable Market (TAM)

The immuno-oncology market is expected to reach hundreds of billions of dollars in the coming years. Compugen is positioned to capture a portion of this TAM through successful development and commercialization of its drug candidates. The size of this TAM will depend heavily on the clinical efficacy of the companyu2019s compounds.

Key Competitors

• ITOS
• GILD
• MRK

Competitive Landscape

Compugen has a competitive advantage in target discovery but faces competition from larger pharmaceutical companies with more resources for late-stage development and commercialization. The market share of each competitor in PVRIG and TIGIT is currently zero as no drugs in this area are approved yet. Future market share will depend on clinical trial success

Historical Growth: Historical growth is characterized by preclinical advances and clinical trial initiations.

Future Projections: Future growth is dependent on the success of clinical trials and expansion of partnerships.

Recent Initiatives: Recent initiatives include advancing COM701 and BAY 1905254 through clinical trials.

Compugen is a clinical-stage biotech company leveraging its computational platform to discover novel cancer immunotherapies. Its strengths lie in its innovative target discovery and partnerships, but it faces challenges with clinical development risks and competition. Successful clinical trials and expanded partnerships are crucial for future growth. They need to look out for negative clinical trial data and competition from bigger pharma companies.

• ITOS
• GILD
• MRK

Data Sources:

• Compugen's investor relations website
• SEC filings
• Analyst reports
• ClinicalTrials.gov

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated and subject to change.